SCHEMBL25802440

SCHEMBL25802440

CN1CCN(Cc2ccc(NC(=O)Oc3ccccc3)cc2F)CC1

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.57
NPSR1 Q6W5P4 1/20 0.57
ABL1 P00519 1/20 0.48
MAPT P10636 3/20 0.48
LMNA P02545 2/20 0.48
SMN1; SMN2 Q16637 1/20 0.47
KIT P10721 4/20 0.47
ALDH1A1 P00352 2/20 0.47
RAD51 Q06609 1/20 0.46
BRAF P15056 1/20 0.46
SRC P12931 1/20 0.46
MCHR1 Q99705 1/20 0.45
MEN1 O00255 1/20 0.45
HTT P42858 1/20 0.45
KMT2A Q03164 1/20 0.45
FLT1 P17948 1/20 0.44
KDR P35968 1/20 0.44
FLT3 P36888 1/20 0.44
CYP1A2 P05177 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25802416 0.87 ALDH1A1 (0.50) GAANPSR1MAPTSMN1; SMN2ALDH1A1
SCHEMBL25802168 0.87 GAA (0.57) GAANPSR1ABL1MAPTLMNA
SCHEMBL2435253 0.86 ABL1 (0.65) GAANPSR1ABL1KITBRAF
Hydrochloric Acid SCHEMBL2435251 0.85 ABL1 (0.64) GAANPSR1ABL1KITBRAF
SCHEMBL25245565 0.84 LMNA (0.56) ABL1MAPTLMNAKITALDH1A1
SCHEMBL29856430 0.83 BRAF (0.62) ABL1MAPTLMNAKITALDH1A1
SCHEMBL30486132 0.80 LMNA (0.55) ABL1MAPTLMNAKITALDH1A1
SCHEMBL29716288 0.79 GAA (0.52) GAANPSR1ABL1MAPTLMNA
SCHEMBL23240068 0.79 GAA (0.52) GAANPSR1ABL1MAPTLMNA
SCHEMBL12982572 0.79 RAD51 (0.55) GAANPSR1MAPTLMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250177382-A1 NEK7 INHIBITORS Halia Therapeutics, Inc. 2025-06-05 US disclosed
US-20230210853-A1 TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME Halia Therapeutics, Inc. 2023-07-06 US disclosed
US-20230210853-A1 TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME Halia Therapeutics, Inc. 2023-07-06 US disclosed
WO-2022226182-A1 NEK7 INHIBITORS Halia Therapeutics, Inc. (US) 2022-10-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230210853-A1 TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME NEK7, NLRP3, NOD1 GAA 3968/4885NPSR1 3866/4885ABL1 4556/4885
US-20250177382-A1 NEK7 INHIBITORS NEK7, NEK5, NEK1 GAA 3869/4885NPSR1 789/4885ABL1 4260/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.